Newly diagnosed? Start here.
What is cutaneous lymphoma?
Cutaneous lymphoma is a general term for many lymphomas of the skin including:
- cutaneous T-cell lymphoma
- mycosis fungoides
- Sézary syndrome
- cutaneous anaplastic large cell lymphoma
- adult T-cell leukemia/lymphoma
- peripheral T-cell lymphoma
- lymphomatoid granulomatosis
- granulomatous slack skin disease
- B-cell lymphoma
- pagetoid reticulosis
- and more read more...
Join our e-mailing list!
Want to get the latest updates on advocacy and research? We send out periodic updates via email, and do not share your email address. Join here
FREE Educational Materials Available
The Cutaneous Lymphoma Foundation has several educational materials available. read more...
National Comprehensive Cancer Network (NCCN) Practice guidelines in Oncology for Mycosis Fungoides/Sezary Syndrome
Here is the link to download the document (MF/SS guidelines are on pages 62-70)
In the News
December 7, 2009: Celegen to Acquire Gloucester Pharmaceuticals
November 5, 2009: FDA Approves Gloucester Pharmaceuticals' ISTODAX® for Patients with Cutaneous T-cell Lymphoma
September 2, 2009: Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
September 2, 2009: FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
July 23, 2009: Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website
June 29, 2009: Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
May 30, 2009: Positive data on oral belinostat in phase I dose escalating study in Lymphoma presented at ASCO
May 26, 2009: Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
March 24, 2009: Allos Therapeutics Appoints David M. Stout to Its Board of Directors
March 23, 2009: U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
March 13, 2009: New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guideleinse for Non-Hodgkin's Lymphomas
October 15, 2008: FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
The most reliable, up-to-date information about cancer is available in Spanish! The National Cancer Institute (NCI) is pleased to announce the launch of a new Spanish Web site, Cancer.gov en español. Information about mycosis fungoides and Sezary syndrome is available en español here. (This link will open in a new window.) |
Cutaneous T-Cell Lymphoma Financial Assistance Program from Patient Services Incorporated
The PSI CTCL Co-pay assistance program is designed to help those eligible afford the cost of their expensive prescription medication (oral and topical). To apply for CTCL financial assistance, please call a PSI Customer Service Representative toll free at (800) 366-7741.
Medicare Formulary Finder for Prescription Drug Plans
The Formulary Finder for Prescription Drug Plans will allow you to find plans in your state that match your required drug list. Click here to visit the Formulary Finder for Prescription Drug Plans on medicare.gov.
What happened to the Mycosis Fungoides Foundation? Read the press release... |
